---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-045035"
form_type: "8-K"
ticker: "PPCB"
cik: "0001517681"
company_name: "Propanc Biopharma, Inc."
filed_at: "2023-12-15T23:59:59+00:00"
generated_at: "2026-06-07T11:51:23.204918+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Propanc Biopharma issues $150K convertible note to One44 Capital at 10% interest, 60% conversion discount

## Summary
- Principal $150K; purchase price $135K (15% OID); 10% interest; maturity Dec 8, 2024.
- Convertible at 60% of lowest trading price over prior 15 days; subject to 4.99% beneficial ownership cap.
- Issued under Regulation D private placement; net proceeds for working capital.
- Prepayment option: 115% within 60 days, 130% 61-120 days, 140% 121-180 days; none after 180 days.

## SEC filing metadata
- accession: 0001493152-23-045035
- form_type: 8-K
- ticker: PPCB
- cik: 0001517681
- company_name: Propanc Biopharma, Inc.
- filed_at: 2023-12-15T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223045035/0001493152-23-045035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223045035/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-045035
- JSON: https://secwatch.observer/filing/0001493152-23-045035.json
- Plain text: https://secwatch.observer/filing/0001493152-23-045035.txt

## Key facts
- Debt Financings
  Propanc Biopharma, Inc. incurred convertible notes of $150,000 with Investor at ten percent (10%) per annum maturing December 8, 2024.
  - Instrument: convertible notes
  - Principal: $150,000
  - Counterparty: Investor
  - Rate: ten percent (10%) per annum
  - Maturity: December 8, 2024
  - Event: incurrence
  source text: entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $150,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223045035/0001493152-23-045035-index.htm
- Material Agreements
  Propanc Biopharma, Inc. entered into Purchase Agreement with an investor valued at principal amount of $150,000 (effective 2023-12-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: an investor
  - Value: principal amount of $150,000
  - Effective: 2023-12-11
  source text: Effective December 11, 2023, Propanc Biopharma, Inc. (the “Company”) entered into and closed a securities purchase agreement (the “Purchase Agreement”) with an investor (the “Investor”), pursuant to which the Investor agreed to purchase a convertible promissory note from the Company in the aggregate principal amount of $150,000 (the “Note”), for a purchase price of $135,000.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223045035/0001493152-23-045035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.